Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$23.00 USD
+0.55 (2.43%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $22.99 -0.01 (-0.04%) 4:50 PM ET
1-Strong Buy of 5 1
D Value D Growth C Momentum D VGM
Price, Consensus and EPS Surprise
CORT 23.00 +0.55(2.43%)
Will CORT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CORT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CORT
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
CORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for April 17th
Corcept (CORT) Completes Enrollment in Phase II ALS Study
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
Other News for CORT
Promising Clinical Outcomes and Market Potential: Buy Rating for Corcept’s Relacorilant
20 companies screened for quality in a cheap part of the stock market
Analysts Are Bullish on These Healthcare Stocks: Corcept Therapeutics (CORT), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter
Corcept falls after phase 3 results on Cushing's candidate doesn't include some data